Description: <b>GEM</b> An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA<br>
Treats cancer of pancreas, lung, ovary and breast.<br>
<br>
<!-- Gemcitabine (dFdC) — Time-Scale Flagged Pathway Table -->
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Inhibition of DNA synthesis (antimetabolite effect)</td>
<td>Incorporated into DNA → chain termination</td>
<td>Normal dividing cells affected (bone marrow, GI epithelium)</td>
<td>P, R, G</td>
<td>Direct cytotoxicity</td>
<td>Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is phosphorylated to the triphosphate form (dFdCTP) which competes with dCTP, gets incorporated into DNA, and blocks DNA chain elongation.</td>
</tr>
<tr>
<td>2</td>
<td>Ribonucleotide reductase (RNR) inhibition</td>
<td>dFdCDP inhibits RNR → deoxynucleotide pool depletion</td>
<td>↔ (normal proliferating cells also impacted)</td>
<td>R, G</td>
<td>Nucleotide pool imbalance</td>
<td>Gemcitabine diphosphate (dFdCDP) inhibits RNR, reducing available dNTPs and enhancing the chain-termination effect.</td>
</tr>
<tr>
<td>3</td>
<td>Apoptosis induction (DNA damage response)</td>
<td>DNA damage signaling → caspase activation</td>
<td>Toxicity in dividing normal tissues</td>
<td>G</td>
<td>Execution of cell death</td>
<td>Prolonged DNA synthesis arrest and replication stress triggers apoptosis pathways via ATR/Chk1, p53, and caspase cascades.</td>
</tr>
<tr>
<td>4</td>
<td>Cell-cycle arrest (S-phase accumulation)</td>
<td>S-phase arrest steers cells into apoptosis</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis → death</td>
<td>Accumulation of stalled replication forks enforces S-phase arrest and amplifies cytotoxicity.</td>
</tr>
<tr>
<td>5</td>
<td>DNA damage response signaling (ATR/Chk1/Chk2)</td>
<td>Checkpoint activation</td>
<td>↔</td>
<td>R, G</td>
<td>Damage signaling</td>
<td>Replication stress activates ATR/Chk1/Chk2 and modulates cell-cycle checkpoints and repair responses.</td>
</tr>
<tr>
<td>6</td>
<td>NF-κB pro-survival signaling (resistance axis)</td>
<td>NF-κB activation can reduce sensitivity</td>
<td>↔</td>
<td>R, G</td>
<td>Resistance/modulation</td>
<td>In some tumor models, NF-κB and other pro-survival axes mediate resistance to gemcitabine cytotoxicity; inhibition sensitizes cells.</td>
</tr>
<tr>
<td>7</td>
<td>Autophagy modulation (response to stress)</td>
<td>Autophagy ↑ in some contexts (cytoprotective)</td>
<td>↔</td>
<td>G</td>
<td>Adaptive stress response</td>
<td>Gemcitabine can induce autophagy as a survival mechanism in some models; autophagy inhibition can sensitize cells in combination studies.</td>
</tr>
<tr>
<td>8</td>
<td>Reactive oxygen species (ROS) elevation (indirect)</td>
<td>ROS ↑ (reported in some models)</td>
<td>↔</td>
<td>G</td>
<td>Stress amplification</td>
<td>Some preclinical studies report ROS increases secondary to replication stress; not a primary mechanism but modulates cell-death pathways.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical resistance mechanisms (CDA, nucleoside transporters)</td>
<td>CDA ↑; hENT1 ↓ correlates with resistance</td>
<td>—</td>
<td>G</td>
<td>Resistance / exposure constraint</td>
<td>Cytidine deaminase (CDA) inactivates gemcitabine; lower hENT1 transport reduces uptake — major clinical resistance factors.</td>
</tr>
<tr>
<td>10</td>
<td>Bioavailability / pharmacokinetics (IV dosing; systemic exposure)</td>
<td>IV infusion achieves systemic levels</td>
<td>↔</td>
<td>—</td>
<td>PK constraint</td>
<td>Gemcitabine is given systemically (often IV) and achieves cytotoxic blood levels; rapid deamination by CDA and short half-life shape dosing.</td>
</tr>
</table>
<p><b>Time-Scale Flag (TSF):</b> P / R / G</p>
<ul>
<li><b>P</b>: 0–30 min (rapid biochemical activation / early metabolic engagement)</li>
<li><b>R</b>: 30 min–3 hr (acute nucleotide pool effects / checkpoint signaling)</li>
<li><b>G</b>: >3 hr (DNA damage response, cell death, phenotype outcomes)</li>
</ul>